- allergy or contraindication to any of the drugs under study. - spo2 <90% (in air ambient) or pao2 <60 mmhg (in ambient air) or pao2/fio2 <300 mmhg. - ongoing treatment with glucocorticoids, immunosuppressive, or biologic drugs with another indication. - decompensated diabetes mellitus. - uncontrolled hypertension. - psychotic or manic disorder. - active cancer. - pregnancy or lactation. - clinical or biochemical suspicion (procalcitonin >0.5 ng/ml) of active infection other than sars-cov-2. - out-of-hospital management patient. - conservative or palliative management patient. - participation in another clinical trial. - any important and uncontrolled medical, psychological, psychiatric, geographic or social problem that contraindicates the patient's participation in the trial or that does not allow adequate follow-up and adherence to the protocol and evaluation of the study results.

- allergy or contraindication to any of the drugs under study. - spo2 <90% (in air ambient) or pao2 <60 mmhg (in ambient air) or pao2/fio2 <300 mmhg. - ongoing treatment with glucocorticoids, immunosuppressive, or biologic drugs with another indication. - decompensated diabetes mellitus. - uncontrolled hypertension. - psychotic or manic disorder. - active cancer. - pregnancy or lactation. - clinical or biochemical suspicion (procalcitonin >0.5 ng/ml) of active infection other than sars-cov-2. - out-of-hospital management patient. - conservative or palliative management patient. - participation in another clinical trial. - any important and uncontrolled medical, psychological, psychiatric, geographic or social problem that contraindicates the patient's participation in the trial or that does not allow adequate follow-up and adherence to the protocol and evaluation of the study results.